KPTI
Karyopharm Therapeutics Inc.Company with tickers: KPTI
CIK
1503802
CUSIP
48576U205
Shares Outstanding
22,662,943
13F Activity (30d)
78 filings
76 filers
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | $35,066,000 | USD | 2026-03-31 | 10-Q | 2026-05-14 |
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | $61,826,000 | USD | 2026-03-31 | 10-Q | 2026-05-14 |
| Research & Development | $33,797,000 | USD | 2026-03-31 | 10-Q | 2026-05-14 |
| Operating Income | $-26,760,000 | USD | 2026-03-31 | 10-Q | 2026-05-14 |
| Net Income | $-22,392,000 | USD | 2026-03-31 | 10-Q | 2026-05-14 |
| EPS (Basic) | $-1.02 | USD/shares | 2026-03-31 | 10-Q | 2026-05-14 |
| EPS (Diluted) | $-1.24 | USD/shares | 2026-03-31 | 10-Q | 2026-05-14 |